Ranexa® Clinical Trials

Ranexa has been studied in multiple clinical trials. The pivotal Phase 3 CARISA trial established the efficacy of Ranexa in treating chronic angina. The TERISA trial assessed Ranexa in patients with chronic angina and type 2 diabetes.

Indication
  • Ranexa is indicated for the treatment of chronic angina.
  • Ranexa may be used with beta-blockers, nitrates, calcium channel blockers, anti-platelet therapy, lipid-lowering therapy, ACE inhibitors, and angiotensin receptor blockers.
CARISA Clinical Trial icon of a person walking

CARISA Clinical Trial

See how Ranexa affected exercise duration, angina symptoms and nitroglycerin use when added to background antianginal therapy.

Learn More
TERISA Clinical Trial; icon of a bar graph

TERISA Clinical Trial

Learn about Ranexa's effects on angina frequency and nitroglycerin use in patients with chronic angina and type 2 diabetes in the TERISA trial.

View the Data
Important Safety Information
Contraindications